Gan & Lee Pharmaceuticals

Call Directions Website Contact the business

Gan & Lee Pharmaceuticals Founded in 1998, Gan&Lee Pharmaceuticals is a high-tech biopharmaceutical China-based company. Curren

Three days in Milan. Conversations to carry forward. 🇮🇹With CPHI Milan 2026 now concluded, we’d like to thank everyone w...
10/10/2026

Three days in Milan. Conversations to carry forward. 🇮🇹

With CPHI Milan 2026 now concluded, we’d like to thank everyone who visited Gan & Lee at Booth 16H25.

It was a pleasure to reconnect with our partners, meet new industry peers, and exchange perspectives on opportunities in metabolic health.

A big thank you to our team for bringing their energy and expertise to Milan.
Let’s stay connected and keep the conversation going.

09/10/2026

Gan & Lee's insulin glargine has received SAHPRA approval in South Africa in both cartridges and prefilled pens.



This is our first product approval in South Africa, laying the foundation for commercialization in the country.



Building on previous approvals in Egypt, Ethiopia, and Algeria, this milestone further strengthens Gan & Lee's presence in Africa and supports our efforts to expand access to high-quality diabetes treatments across the region.



Learn More: https://www.ganlee.com/detail/872.html



Every Step Matters. Every Step Can Make a Difference.What if every step we take could help bring health and care to thos...
08/10/2026

Every Step Matters. Every Step Can Make a Difference.

What if every step we take could help bring health and care to those around us?

This September, 721 employees of Gan & Lee Pharmaceuticals took part in an employee charity step campaign, contributing more than 22 million steps. Their steps were converted into RMB 85,800 (approximately USD 12,000) in charitable funds, which helped support our “Every Moment Matters, Health for All” community health initiative in Beijing.

Together with Beijing Leyu Charity Foundation, we brought health services directly into local communities during Tencent’s “99 Giving Day” campaign.

Across five community activities, our teams and healthcare professionals provided residents with:
• Blood pressure, blood glucose, BMI and waist circumference checks
• Diabetic retinopathy screening
• Health consultations and guidance on diet, exercise and daily health management
• Educational activities on diabetes and chronic disease management

We also provided targeted financial assistance to more than 30 residents facing both chronic illness and financial difficulties, helping ensure that support reached those who needed it most.

More than 300 community residents have benefited from the initiative so far.
From one employee’s step to millions of steps, from an online charity campaign to tangible action in the community, every step became part of a larger commitment to health.

At Gan & Lee Pharmaceuticals, we believe that our responsibility as a healthcare company goes beyond providing medicines. We are committed to exploring meaningful ways to contribute our expertise and resources to healthier communities.

Every step matters. Let health walk with everyone.

Hello from Milan—CPHI Milan 2026 starts today! The Gan & Lee team is here and ready to welcome you to Booth 16H25.Throug...
06/10/2026

Hello from Milan—CPHI Milan 2026 starts today!

The Gan & Lee team is here and ready to welcome you to Booth 16H25.
Throughout this three-day exhibition, we look forward to exchanging perspectives with the global pharmaceutical community and exploring opportunities for collaboration in metabolic health.

Come by to meet our team, discover more about Gan & Lee, and tell us about your priorities. Whether you have a specific partnership opportunity in mind or simply want to get to know us, we’d be delighted to connect.

📅 6–8 October 2026
📍 Fiera Milano, Italy
🔹 Booth 16H25
The conversations start today. See you at our booth!

Only 3 days to go! ⏳🇮🇹CPHI Milan 2026 is almost here, and the Gan & Lee team is looking forward to meeting you.As you pl...
03/10/2026

Only 3 days to go! ⏳🇮🇹

CPHI Milan 2026 is almost here, and the Gan & Lee team is looking forward to meeting you.
As you plan your time at the exhibition, make Booth 16H25 one of your stops. Come and learn more about our focus on metabolic health, meet the people behind our work, and explore opportunities to collaborate.
We look forward to reconnecting with longstanding partners and making new connections in Milan.

📅 6–8 October 2026
📍 Fiera Milano, Italy
🔹 Booth 16H25
Let’s make time to connect. Message us to arrange a meeting, or visit our booth during the show.
See you in three days!

02/10/2026

EASD 2026 Highlights 👏

The 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD 2026) was held in Milan, Italy, on September 28, 2026. At this year's congress, Gan & Lee Pharmaceuticals showcased new clinical results for insulin ludefen, its investigational once-weekly basal insulin, underscoring the company's continued progress in insulin innovation and its growing visibility within the global diabetes community.

Learn More: https://www.ganlee.com/detail/870.html

Working together to bring medicines closer to patients. 🌏On September 19, Gan & Lee joined regulators from Brazil’s ANVI...
25/09/2026

Working together to bring medicines closer to patients. 🌏

On September 19, Gan & Lee joined regulators from Brazil’s ANVISA and Indonesia’s BPOM at a DIA-hosted meeting in Beijing to exchange perspectives on pharmaceutical innovation and international cooperation.

Through our insulin partnership in Brazil and local manufacturing collaborations in Indonesia, we’re supporting local production and improving access to medicines.
We look forward to deepening these connections with patients’ needs at the heart of our work.

Learn More: https://www.ganlee.com/detail/869.html

22/09/2026

New research. Shared perspectives. See you at EASD 2026.

Gan & Lee will give seven research presentations in Milan, spanning once-weekly insulin ludefen, once-daily basal insulin GZR33, twice-monthly GLP-1 RA bofanglutide, and the once-weekly fixed-ratio combination GZR102.

Our oral presentations will feature the SUPER-1 and SUPER-2 studies of insulin ludefen, alongside the first clamp study data for GZR33. Four short oral discussions will highlight additional research on insulin ludefen, bofanglutide, and GZR102.

📅 Our presentations: 29 September–1 October 2026
📍 Milan Convention Centre

See you in Milan! 🇮🇹Gan & Lee is heading to CPHI Milan 2026!We look forward to joining partners and industry peers from ...
21/09/2026

See you in Milan! 🇮🇹

Gan & Lee is heading to CPHI Milan 2026!
We look forward to joining partners and industry peers from around the world for three days of conversations, new connections, and opportunities for collaboration.

With a focus on advancing metabolic health worldwide, we’re excited to share more about our work and explore how we can work together.

Whether you’re a familiar face or connecting with us for the first time, we invite you to visit Booth 16H25 and meet our team.

📅 6–8 October 2026
📍 Fiera Milano, Italy
🔹 Booth 16H25

Will you be in Milan? Get in touch to arrange a meeting, or stop by our booth during the exhibition.

We are pleased to announce Gan & Lee Pharmaceuticals has entered into an exclusive license agreement with the multinatio...
04/09/2026

We are pleased to announce Gan & Lee Pharmaceuticals has entered into an exclusive license agreement with the multinational biopharmaceutical company The Menarini Group.

Under the agreement, the parties will collaborate on the registration and commercialization of Gan & Lee's independently developed GLP-1 RA, bofanglutide (development code: GZR18), under development for the treatment of adults with obesity or overweight, administered once every two weeks.

Under the agreement, Gan & Lee is eligible to receive an upfront payment of EUR 62million, milestone payments totaling up to EUR 664million, and double-digit royalties on net sales in the licensed territory. The aggregate potential deal value is up to EUR 726million, excluding royalties.

Menarini will be responsible for regulatory submissions and commercialization in the licensed territory in a total of 39 countries: the 27 Member States of the European Union; the United Kingdom, Switzerland, Norway, Iceland, Liechtenstein and Balkans countries.

This agreement marks a strategic milestone in Menarini's mission to expand its footprint in the metabolic space, a critical area that affects an increasingly broad patients' population in need.

Read the full press release: https://www.ganlee.com/detail/863.html

Address

通州区漷县镇南凤西一路8号
Beijing

Alerts

Be the first to know and let us send you an email when Gan & Lee Pharmaceuticals posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Gan & Lee Pharmaceuticals:

Shortcuts

Share